RE:RE:Exposure & AwarenessDr. Kamat's comments in May 2018 when the Phase 1b was completed were very encouraging. Hopefully he will be even more enthusiastic about TLD1433 pdt in the near future.
"If a larger multicenter study demonstrates efficacy of PDT technology in this patient population, it would provide our patients a useful alternative to avoid radical surgery. The more safe, reliable options we have to offer our patients, the better it is for everyone concerned. The MSAB thus recommended that the Company truncate the Study early to seek Health Canada and FDA approval to commence a larger and more statistically powered, single arm, multicenter efficacy study. Moreover, the MSAB reviewed and approved in principle the Phase II clinical protocol and the clinical study design presented by Dr. Jewett. BCG-Unresponsive NMIBC is a potentially fatal disease that requires additional treatment options. Currently, cystectomy remains the safest treatment option available to patients, but if the Theralase PDT achieves its efficacy endpoint in a Phase II clinical study, then this will present patients with an attractive additional treatment option. The clinical data presented by Dr. Kulkarni suggests that the Theralase PDT treatment option may be just what the doctor ordered.” Gman620 wrote:
Dr. Kamat was/is my doctor and was one of the main reasons I got into this stock a while back, when I saw his name listed in the company material. I hope he stays involved.